Get the Stockscreener App
2.51
11.06%
0.25
Vivosim Labs Inc stock is traded at $2.51, with a volume of 157.79K.
It is up +11.06% in the last 24 hours and up +30.05% over the past month.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
See More
Previous Close:
$2.26
Open:
$2.19
24h Volume:
157.79K
Relative Volume:
0.58
Market Cap:
$6.53M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.87%
1M Performance:
+30.05%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.06
$2.58
1-Week Range:
$2.06
$3.10
52-Week Range:
$1.41
$3.10
Vivosim Labs Inc Stock (VIVS) Company Profile
Name
Vivosim Labs Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
2.51 | 5.88M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Vivosim Labs Inc Stock (VIVS) Latest News
Developing predictive dashboards with VivoSim Labs Inc. data2025 AllTime Highs & Risk Controlled Stock Alerts - Newser
Can VivoSim Labs Inc. hit a new high this monthBull Run & Technical Pattern Based Signals - Newser
Applying chart zones and confluence areas to VivoSim Labs Inc.Trade Volume Report & Low Risk High Win Rate Stock Picks - Newser
What’s the recovery path for long term holders of VivoSim Labs Inc.Analyst Downgrade & Fast Entry High Yield Stock Tips - Newser
Is it too late to sell VivoSim Labs Inc.Portfolio Risk Summary & Reliable Entry Point Trade Alerts - Newser
Does VivoSim Labs Inc. fit your quant trading modelBuy Signal & Comprehensive Market Scan Insights - Newser
Is now a turning point for VivoSim Labs Inc.Trade Entry Report & Fast Entry High Yield Stock Tips - Newser
What MACD and RSI say about VivoSim Labs Inc.July 2025 Recap & Capital Protection Trade Alerts - Newser
Can momentum traders help lift VivoSim Labs Inc.July 2025 Gainers & Free Growth Oriented Trading Recommendations - Newser
Building trade automation scripts for VivoSim Labs Inc.2025 Top Gainers & Reliable Price Breakout Alerts - Newser
Has VivoSim Labs Inc. found a price floorMarket Growth Report & Risk Managed Investment Entry Signals - Newser
Is VivoSim Labs Inc. a play on infrastructure spendingWeekly Gains Report & Reliable Price Breakout Signals - خودرو بانک
Is a relief rally coming for VivoSim Labs Inc. holdersWeekly Stock Report & Low Volatility Stock Recommendations - Newser
VivoSim appoints Lialin as Chief Commercial Officer - MSN
How to forecast VivoSim Labs Inc. trends using time series2025 Fundamental Recap & Low Risk Growth Stock Ideas - Newser
Regression analysis insights on VivoSim Labs Inc. performance2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
Is VivoSim Labs Inc. stock ready for a breakoutWeekly Earnings Recap & Fast Exit/Entry Strategy Plans - Newser
Can VivoSim Labs Inc. recover in the next quarterMarket Risk Analysis & Fast Moving Trade Plans - Newser
Sector ETF performance correlation with VivoSim Labs Inc.New Guidance & High Accuracy Trade Signal Alerts - Newser
Can swing trading help recover from VivoSim Labs Inc. lossesTrade Signal Summary & Short-Term High Return Strategies - Newser
Chart based exit strategy for VivoSim Labs Inc.Long Setup & Accurate Entry/Exit Alerts - Newser
Can technical indicators confirm VivoSim Labs Inc.’s reversalJuly 2025 Trends & Low Risk Profit Maximizing Plans - Newser
How to interpret RSI for VivoSim Labs Inc. stockMarket Performance Report & Verified Short-Term Trading Plans - Newser
Is VivoSim Labs Inc. stock entering bullish territory2025 Momentum Check & Weekly Sector Rotation Insights - Newser
Using data filters to optimize entry into VivoSim Labs Inc.Weekly Trade Summary & Growth-Oriented Investment Plans - Newser
How cyclical is VivoSim Labs Inc.’s revenue stream2025 Pullback Review & Free Safe Capital Growth Stock Tips - خودرو بانک
Will VivoSim Labs Inc. continue its uptrend2025 Volatility Report & Free Technical Confirmation Trade Alerts - Newser
Will VivoSim Labs Inc. outperform its industry peers2025 Volume Leaders & High Yield Equity Trading Tips - خودرو بانک
Aug Shorts: Is VivoSim Labs Inc. stock a top performer YTDMarket Growth Review & Free Growth Oriented Trading Recommendations - خودرو بانک
Vivosim Labs Inc Stock (VIVS) Financials Data
There is no financial data for Vivosim Labs Inc (VIVS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):